Press Release

Two leading university hospitals implement Kaiku Health in Central Europe

Kaiku Health will provide digital health interventions based on patient-reported outcomes to cancer patients treated with chemotherapy, immunotherapy and combination therapies in several cancer types.

Kaiku Health is strengthening its foothold in Central Europe as the Geneva University Hospitals (HUG) in Switzerland and University Hospital Schleswig-Holstein Lübeck in Germany will implement Kaiku Health in the symptom management and patient-reported outcome monitoring of their cancer patients.

Kaiku Health was piloted at the Geneva University Hospitals (HUG) in 2019. The platform will be gradually provided for all patients who receive chemotherapy for local or metastatic breast, colorectal or lung cancer.

In local cancers Kaiku Health is used to monitor and manage patients’ symptoms. Symptom tracking in the follow-up module is designed based on research results which show that digital monitoring of certain symptoms during chemotherapy treatment can improve patients’ quality of life (1) and increase the overall survival of cancer patients (2). Patients with metastatic cancers will use the platform to report their quality of life to their care teams.

Managing immune-related toxicities with Kaiku Health

University Hospital Schleswig-Holstein Lübeck will implement Kaiku Health into the monitoring and management of toxicities of lung cancer patients treated with immunotherapies and receiving either mono- or combination therapies.

The development of Kaiku Health immune checkpoint inhibitor (ICI) module began in late 2015 and entered a multi-center clinical validation in 2017. The algorithms of the module screen for signs of immune-mediated adverse events, provide automated instructions for patients and alert the care team in the presence of unfavourable developments. First retrospective results of the ICI module were published earlier this year.

“Central Europe has been the fastest growing area for us recently, and we are excited to start our cooperation with these two renowned university hospitals. Working with leading professionals is important for us so that we can better understand the implications in symptom management in these patient groups and these novel therapies”, concludes Marko Kuisma, Chief Commercial Officer of Kaiku Health.

Kaiku Health is a Class 1 Medical Device in cancer care, providing digital health interventions based on patient-reported outcomes. Kaiku Health has modules for over 25 cancer types across different cancer care pathways. It is currently in use in over 40 European cancer clinics and hospitals.

 For more information contact:

Marko Kuisma
Chief Commercial Officer
+358 50 377 3084


(1) Basch E, Allison MD, Mark GK, Howard IS, Clifford AH, Paul S. Symptom Monitoring With Patient- Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial, J Clin Oncol 2016: 34(6), 557–565
(2) Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, Schrag D. Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA. 2017 Jul 11; 318(2): 197–198.

UKSH Compliance Note:
The cooperation partners confirm that the present transaction does not affect further sales transactions of UKSH (in particular procurement transactions and pricing) and that there are no expectations in this regard.


Get in touch with us

Interested in learning more about Kaiku Health? Send us a note